<code id='6ACC8938CF'></code><style id='6ACC8938CF'></style>
    • <acronym id='6ACC8938CF'></acronym>
      <center id='6ACC8938CF'><center id='6ACC8938CF'><tfoot id='6ACC8938CF'></tfoot></center><abbr id='6ACC8938CF'><dir id='6ACC8938CF'><tfoot id='6ACC8938CF'></tfoot><noframes id='6ACC8938CF'>

    • <optgroup id='6ACC8938CF'><strike id='6ACC8938CF'><sup id='6ACC8938CF'></sup></strike><code id='6ACC8938CF'></code></optgroup>
        1. <b id='6ACC8938CF'><label id='6ACC8938CF'><select id='6ACC8938CF'><dt id='6ACC8938CF'><span id='6ACC8938CF'></span></dt></select></label></b><u id='6ACC8938CF'></u>
          <i id='6ACC8938CF'><strike id='6ACC8938CF'><tt id='6ACC8938CF'><pre id='6ACC8938CF'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:Wikipedia    Page View:94

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In